MCID: TCK001
MIFTS: 50

Tick-Borne Encephalitis malady

Categories: Rare diseases, Neuronal diseases, Infectious diseases

Aliases & Classifications for Tick-Borne Encephalitis

Aliases & Descriptions for Tick-Borne Encephalitis:

Name: Tick-Borne Encephalitis 12 50 56 14 69
Siberian Tick-Borne Encephalitis 12 69
Western European Tick-Borne Encephalitis 12
Russian Spring-Summer Encephalitis 12
Encephalitis, Far Eastern Russian 69
Encephalitis, Central European 69
Central European Encephalitis 12
West-Siberian Encephalitis 12
Encephalitis, Tick-Borne 42
Encephalitis Tick-Borne 52
Taiga Encephalitis 12
Far Eastern Tbe 12

Characteristics:

Orphanet epidemiological data:

56
tick-borne encephalitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050175
ICD10 33 A84.1
ICD9CM 35 063.2
MeSH 42 D004675
SNOMED-CT 64 16901001
Orphanet 56 ORPHA297
MESH via Orphanet 43 D004675
UMLS via Orphanet 70 C0014061
ICD10 via Orphanet 34 A84.0 A84.1 A84.8 more
UMLS 69 C0014054

Summaries for Tick-Borne Encephalitis

Disease Ontology : 12 A viral infectious disease that results_in inflammation located in brain, has material basis in Tick-borne encephalitis virus, which is transmitted_by Ixodes ticks. The infection has symptom drowsiness, has symptom confusion, has symptom sensory disturbances, and has symptom paralysis.

MalaCards based summary : Tick-Borne Encephalitis, also known as siberian tick-borne encephalitis, is related to encephalitis and powassan encephalitis, and has symptoms including drowsiness, confusion and sensory disturbances. An important gene associated with Tick-Borne Encephalitis is SCRIB (Scribbled Planar Cell Polarity Protein), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Formaldehyde and Dimenhydrinate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and t cells.

Wikipedia : 71 Tick-borne encephalitis (TBE) is a viral infectious disease involving the central nervous system. The... more...

Related Diseases for Tick-Borne Encephalitis

Diseases related to Tick-Borne Encephalitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
id Related Disease Score Top Affiliating Genes
1 encephalitis 11.3
2 powassan encephalitis 11.1
3 west nile virus 10.3
4 ehrlichiosis 10.2
5 hereditary elliptocytosis 10.2 OAS1 OAS3
6 thrombocytopenia 10.2
7 japanese encephalitis 10.2
8 methylmalonic aciduria and homocystinuria, cblj type 10.2 OAS1 OAS3
9 vestibule of mouth cancer 10.1 IL10 TLR3
10 venezuelan equine encephalitis 10.1
11 hemorrhagic fever 10.1
12 louping ill 10.1
13 tick infestation 10.1
14 osteodysplasty precocious of danks mayne and kozlowski 10.1 CCR5 IL10
15 lepromatous leprosy 10.1 IL10 OAS1
16 mineral metabolism disease 10.1 CD209 OAS1 OAS3
17 primary laryngeal lymphangioma 10.1 CXCL10 CXCL11
18 optic pathway glioma 10.0 CXCL10 CXCL11
19 kyasanur forest disease 10.0
20 herpes simplex 10.0
21 lyme disease 10.0
22 crimean-congo hemorrhagic fever 10.0
23 vaccinia 10.0
24 human granulocytic anaplasmosis 10.0
25 transmitted_by 10.0
26 herpes simplex encephalitis 10.0
27 meningoencephalitis 10.0
28 neuronitis 10.0
29 coumarin resistance 10.0 CXCL10 CXCL11
30 depressed scar 10.0 CD209 IL10 TLR3
31 sexual masochism 10.0 CD209 CXCL10 TLR3
32 anus leiomyosarcoma 10.0 CCR5 CD209 IL10
33 hereditary alpha tryptasemia syndrome 10.0 CD209 IL10
34 hepatitis c virus 9.9 CCR5 CD209 OAS1 TLR3
35 pulpitis 9.9 CXCL10 IL10
36 fallopian tube serous adenocarcinoma 9.9 CXCL10 IL10
37 immunodeficiency due to a late component of complement deficiency 9.9 CXCL10 IL10
38 proximal symphalangism 9.9 CCR5 CXCL10 IL10
39 measles 9.9
40 optic neuritis 9.9
41 rubella 9.9
42 narcolepsy 9.9
43 rift valley fever 9.9
44 meningitis 9.9
45 hepatitis 9.9
46 neuritis 9.9
47 hepatitis b 9.9
48 tularemia 9.9
49 omsk hemorrhagic fever 9.9
50 purpura 9.9

Graphical network of the top 20 diseases related to Tick-Borne Encephalitis:



Diseases related to Tick-Borne Encephalitis

Symptoms & Phenotypes for Tick-Borne Encephalitis

Symptoms:

12
  • drowsiness
  • confusion
  • sensory disturbances
  • paralysis

Drugs & Therapeutics for Tick-Borne Encephalitis

Drugs for Tick-Borne Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Formaldehyde Approved, Vet_approved Phase 4,Phase 3 50-00-0 712
2
Dimenhydrinate Approved Phase 4 523-87-5 441281
3 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
4 Antibodies Phase 4
5 Immunoglobulins Phase 4
6 Anti-Infective Agents Phase 4,Phase 3
7 Disinfectants Phase 4,Phase 3
8 Pharmaceutical Solutions Phase 4
9
Lactitol Phase 3 585-86-4 3871
10
Acetaminophen Approved 103-90-2 1983
11
Doxycycline Approved, Investigational, Vet_approved 564-25-0 54671203
12
Granisetron Approved, Investigational 109889-09-0 3510
13
Ceftriaxone Approved 73384-59-5 5479530 5361919
14
Dopamine Approved 51-61-6, 62-31-7 681
15 Anti-Bacterial Agents
16 Antibiotics, Antitubercular
17 Antiemetics
18 Antimalarials
19 Antiparasitic Agents
20 Antiprotozoal Agents
21 Antipyretics
22 dipyrone
23 Acyclovir
24 Antiviral Agents
25 Autonomic Agents
26 Dopamine Agents
27 Dopamine Antagonists
28 Gastrointestinal Agents
29 Neurotransmitter Agents
30 Peripheral Nervous System Agents

Interventional clinical trials:

(show all 38)
id Name Status NCT ID Phase
1 TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209) Completed NCT00161967 Phase 4
2 Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules Completed NCT01562444 Phase 4
3 TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223) Completed NCT00503529 Phase 4
4 An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE Completed NCT01106482 Phase 4
5 Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years Completed NCT00161954 Phase 4
6 Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac Completed NCT01710189 Phase 4
7 Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults Completed NCT00311493 Phase 4
8 Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children Completed NCT00311441 Phase 4
9 Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children Completed NCT00163618 Phase 4
10 Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225) Completed NCT00163540 Phase 4
11 Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination Completed NCT00804219 Phase 4
12 TBE Seropersistence up to 10 Years After First Booster in Adults Completed NCT01582698 Phase 4
13 Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years Completed NCT00452621 Phase 4
14 Influence of Persistent CMV-infection on Immune Senescence Completed NCT00461695 Phase 4
15 Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years Completed NCT00161785 Phase 4
16 TBE Vaccination in Allergic Patients Recruiting NCT02511535 Phase 4
17 Tick-Borne Encephalitis (TBE) Seropersistence After First Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401) Active, not recruiting NCT00894686 Phase 4
18 Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children Completed NCT00840801 Phase 3
19 FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years Completed NCT00161876 Phase 3
20 Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years Completed NCT00161746 Phase 2, Phase 3
21 Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR Completed NCT00161824 Phase 3
22 Humoral Response to Tick-borne Encephalitis Vaccine in Elderly Completed NCT01361776 Phase 2, Phase 3
23 Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule Completed NCT00460486 Phase 3
24 Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years Completed NCT00161863 Phase 3
25 Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines Completed NCT00644059 Phase 3
26 New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly Active, not recruiting NCT02318069 Phase 2, Phase 3
27 Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine Unknown status NCT00890422 Phase 2
28 FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years Completed NCT00161889 Phase 2
29 FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years Completed NCT00161850 Phase 2
30 Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years. Completed NCT00161798 Phase 2
31 Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years. Completed NCT00161772 Phase 2
32 Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients Recruiting NCT01991067 Phase 2
33 A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory Terminated NCT01031537 Phase 2
34 Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults Completed NCT00118924 Phase 1
35 Postencephalitic Symptoms After Tick Borne Encephalitis Unknown status NCT00941590
36 Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis Completed NCT02275741
37 Tick-borne Encephalitis and Positive Borrelial Antibodies Recruiting NCT02463942
38 Aseptic Meningoencephalitis in Slovenia Recruiting NCT02328469

Search NIH Clinical Center for Tick-Borne Encephalitis

Cochrane evidence based reviews: encephalitis, tick-borne

Genetic Tests for Tick-Borne Encephalitis

Anatomical Context for Tick-Borne Encephalitis

MalaCards organs/tissues related to Tick-Borne Encephalitis:

39
Brain, Testes, T Cells, Neutrophil, B Cells, Liver, Nk Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Tick-Borne Encephalitis:

18
Brain

Publications for Tick-Borne Encephalitis

Articles related to Tick-Borne Encephalitis:

(show top 50) (show all 633)
id Title Authors Year
1
Human Tick-Borne Encephalitis, the Netherlands. ( 27938522 )
2017
2
Deep sequencing analysis of tick-borne encephalitis virus from questing ticks at natural foci reveals similarities between quasispecies pools of the virus. ( 28073402 )
2017
3
COMPARISON BETWEEN PROTON MAGNETIC RESONANCE SPECTROSCOPY FINDINGS IN DOGS WITH TICK-BORNE ENCEPHALITIS AND CLINICALLY NORMAL DOGS. ( 27714889 )
2017
4
Travel-Related Tick-Borne Encephalitis, Israel, 2006-2014. ( 27779467 )
2017
5
Tick-borne encephalitis virus neutralization by high dose intravenous immunoglobulin. ( 27884572 )
2017
6
Cyclic patterns in the central European tick-borne encephalitis incidence series. ( 27772539 )
2017
7
An outbreak of tick-borne encephalitis associated with raw goat milk and cheese consumption, Croatia, 2015. ( 27364148 )
2016
8
Author's reply: The first tick-borne encephalitis case in the Netherlands: reflections and a note of caution. ( 27719758 )
2016
9
The occurrence of Ixodes ricinus ticks and important tick-borne pathogens in areas with high tick-borne encephalitis prevalence in different altitudinal levels of the Czech Republic Part I. Ixodes ricinus ticks and tick-borne encephalitis virus. ( 27467329 )
2016
10
Tick-Borne Encephalitis sequelae at long-term follow-up: a self-reported case-control study. ( 26810689 )
2016
11
Post Tick-Borne Encephalitis Virus Vaccination Narcolepsy with Cataplexy. ( 27397572 )
2016
12
Cerebral glucose hypometabolism in Tick-Borne Encephalitis, a pilot study in 10 Patients. ( 27418580 )
2016
13
TICK-BORNE ENCEPHALITIS VIRUS INFECTION IN HUMANS. ( 27506096 )
2016
14
Autonomic and peripheral nervous system function in acute tick-borne encephalitis. ( 27247855 )
2016
15
Revisiting Recombination Signal in the Tick-Borne Encephalitis Virus: A Simulation Approach. ( 27760182 )
2016
16
A Density Map of the Tick-Borne Encephalitis and Lyme Borreliosis Vector Ixodes ricinus (Acari: Ixodidae) for Germany. ( 27498885 )
2016
17
Predictors, Neuroimaging Characteristics and Long-Term Outcome of Severe European Tick-Borne Encephalitis: A Prospective Cohort Study. ( 27111657 )
2016
18
Tick-Borne Encephalitis Virus Structural Proteins Are the Primary Viral Determinants of Non-Viraemic Transmission between Ticks whereas Non-Structural Proteins Affect Cytotoxicity. ( 27341437 )
2016
19
Tick-borne encephalitis-still on the map: Report of the 18th annual meeting of the international scientific working group on tick-borne encephalitis (ISW-TBE). ( 27189584 )
2016
20
Complete Genome Sequence of a Low-Virulence Tick-Borne Encephalitis Virus Strain. ( 27795275 )
2016
21
Utilisation of ISA Reverse Genetics and Large-Scale Random Codon Re-Encoding to Produce Attenuated Strains of Tick-Borne Encephalitis Virus within Days. ( 27548676 )
2016
22
The role of the poly(A) tract in the replication and virulence of tick-borne encephalitis virus. ( 27982069 )
2016
23
NK Cell Responses to Human Tick-Borne Encephalitis Virus Infection. ( 27543616 )
2016
24
Prevalence estimation of tick-borne encephalitis virus (TBEV) antibodies in dogs from Finland using novel dog anti-TBEV IgG MAb-capture and IgG immunofluorescence assays based on recombinant TBEV subviral particles. ( 27189583 )
2016
25
Biomarkers in Cerebrospinal Fluid of Children with Tick-Borne Encephalitis: Association with Long-Term Outcome. ( 27187756 )
2016
26
Detection of West Nile virus and tick-borne encephalitis virus in birds in Slovakia, using a universal primer set. ( 27001305 )
2016
27
Association of IL28B and IL10 gene polymorphism with predisposition to tick-borne encephalitis in a Russian population. ( 27068548 )
2016
28
Tick-borne encephalitis virus induces chemokine RANTES expression via activation of IRF-3 pathway. ( 27576490 )
2016
29
The expression of the chemokine receptor CCR5 in tick-borne encephalitis. ( 26906062 )
2016
30
IgG Avidity: an Important Serologic Marker for the Diagnosis of Tick-Borne Encephalitis Virus Infection. ( 27282004 )
2016
31
The occurrence of Ixodes ricinus ticks and important tick-borne pathogens in areas with high tick-borne encephalitis prevalence in different altitudinal levels of the Czech Republic Part II. Ixodes ricinus ticks and genospecies of Borrelia burgdorferi sensu lato complex. ( 27690476 )
2016
32
Serological evidence of tick-borne encephalitis virus infection in moose and deer in Finland: sentinels for virus circulation. ( 26825371 )
2016
33
First human case of tick-borne encephalitis virus infection acquired in the Netherlands, July 2016. ( 27562931 )
2016
34
Letter to the editor: The first tick-borne encephalitis case in the Netherlands: reflections and a note of caution. ( 27719753 )
2016
35
Baltic lineage of tick-borne encephalitis virus: A putative evolutionary pathway. ( 27478072 )
2016
36
Structure-activity relationships of nucleoside analogues for inhibition of tick-borne encephalitis virus. ( 27476046 )
2016
37
Expression of a second open reading frame present in the genome of tick-borne encephalitis virus strain Neudoerfl is not detectable in infected cells. ( 26924586 )
2016
38
Recombinant domains III of Tick-Borne Encephalitis Virus envelope protein in combination with dextran and CpGs induce immune response and partial protectiveness against TBE virus infection in mice. ( 27717318 )
2016
39
Generation and Characterization of a Chimeric Tick-Borne Encephalitis Virus Attenuated Strain ChinTBEV. ( 27076137 )
2016
40
The role of particular tick developmental stages in the circulation of tick-borne pathogens affecting humans in Central Europe. 2. Tick-borne encephalitis virus. ( 27262951 )
2016
41
Epidemiological and clinical features of tick-borne encephalitis in north-western region in Belarus ( 27883379 )
2016
42
Tick-Borne Encephalitis Virus Diversity in Ixodid Ticks and Small Mammals in South-Western Siberia, Russia. ( 27303915 )
2016
43
Comparison of hyponatremia and SIADH frequency in patients with tick borne encephalitis and meningitis of other origin. ( 26785285 )
2016
44
MRI and planimetric CT follow-up study of patients with severe tick-borne encephalitis. ( 26414745 )
2016
45
Virucidal activity of Haemaphysalis longicornis longicin P4 peptide against tick-borne encephalitis virus surrogate Langat virus. ( 26830840 )
2016
46
Epidemiology of tick-borne encephalitis (TBE) in international travellers to Western/Central Europe and conclusions on vaccination recommendations. ( 27087558 )
2016
47
Development of a serodiagnostic multi-species ELISA against tick-borne encephalitis virus using subviral particles. ( 26969490 )
2016
48
Molecular detection of severe fever with thrombocytopenia syndrome and tick-borne encephalitis viruses in ixodid ticks collected from vegetation, Republic of Korea, 2014. ( 27211914 )
2016
49
Human Tick-Borne Encephalitis and Characterization of Virus from Biting Tick. ( 27434395 )
2016
50
Tick-borne encephalitis: What travelers should know when visiting an endemic country. ( 27715427 )
2016

Variations for Tick-Borne Encephalitis

Expression for Tick-Borne Encephalitis

Search GEO for disease gene expression data for Tick-Borne Encephalitis.

Pathways for Tick-Borne Encephalitis

Pathways related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.4 CCR5 CD209 CXCL10 GSN IFNL3 IL10
2
Show member pathways
12.96 CCR5 CXCL10 IFNL3 IL10 OAS1 OAS3
3
Show member pathways
12.61 CXCL10 CXCL11 IL10 TLR3
4
Show member pathways
12.49 CD209 IFNL3 OAS1 OAS3 TLR3
5 12.12 CXCL10 IL10 OAS1 TLR3
6
Show member pathways
12.05 CD209 CXCL10 OAS1 OAS3 TLR3
7 11.99 CCR5 GSN SCRIB
8
Show member pathways
11.82 IL10 OAS1 OAS3
9 11.75 OAS1 OAS3 TLR3
10
Show member pathways
11.67 CCR5 CXCL10 CXCL11
11 11.12 CXCL10 OAS1
12 11.06 CXCL10 CXCL11
13 10.9 CXCL10 CXCL11 IL10
14
Show member pathways
10.84 IFNL3 OAS1
15 10.49 CCR5 CXCL10 IL10

GO Terms for Tick-Borne Encephalitis

Cellular components related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 CD209 CXCL10 CXCL11 GSN IFNL3 IL10
2 external side of plasma membrane GO:0009897 9.33 CCR5 CD209 CXCL10
3 extracellular space GO:0005615 9.1 CXCL10 CXCL11 GSN IFNL3 IL10 OAS3

Biological processes related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.84 CD209 OAS1 OAS3 TLR3
2 innate immune response GO:0045087 9.77 CD209 IFNL3 OAS1 OAS3 TLR3
3 cell-cell signaling GO:0007267 9.76 CCR5 CXCL10 CXCL11 IL10
4 response to lipopolysaccharide GO:0032496 9.75 CXCL10 CXCL11 IL10
5 chemotaxis GO:0006935 9.72 CCR5 CXCL10 CXCL11
6 defense response GO:0006952 9.7 CXCL10 CXCL11 TLR3
7 cellular response to lipopolysaccharide GO:0071222 9.69 CCR5 CXCL10 IL10
8 inflammatory response GO:0006954 9.65 CCR5 CXCL10 CXCL11 IL10 TLR3
9 chemokine-mediated signaling pathway GO:0070098 9.61 CCR5 CXCL10 CXCL11
10 negative regulation of mitotic cell cycle GO:0045930 9.57 IL10 SCRIB
11 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 9.56 CXCL10 CXCL11
12 negative regulation of viral genome replication GO:0045071 9.5 IFNL3 OAS1 OAS3
13 positive regulation of cAMP-mediated signaling GO:0043950 9.49 CXCL10 CXCL11
14 T cell chemotaxis GO:0010818 9.48 CXCL10 CXCL11
15 response to virus GO:0009615 9.46 CXCL10 OAS1 OAS3 TLR3
16 immune response GO:0006955 9.43 CCR5 CXCL10 CXCL11 IL10 OAS1 OAS3
17 positive regulation of cAMP metabolic process GO:0030816 9.4 CXCL10 CXCL11
18 defense response to virus GO:0051607 9.02 CXCL10 IFNL3 OAS1 OAS3 TLR3

Molecular functions related to Tick-Borne Encephalitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 double-stranded RNA binding GO:0003725 9.33 OAS1 OAS3 TLR3
2 CXCR3 chemokine receptor binding GO:0048248 9.26 CXCL10 CXCL11
3 cytokine activity GO:0005125 9.26 CXCL10 CXCL11 IFNL3 IL10
4 2-5-oligoadenylate synthetase activity GO:0001730 8.62 OAS1 OAS3

Sources for Tick-Borne Encephalitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....